CD38 and Miyoshi myopathy: The introduction of immunomodulatory drugs (IMiDs), proteasome inhibitors (PIs), and anti-CD38 monoclonal antibodies (anti-CD38 Abs) has led to a significant improvement in the outcome of patients with MM [2].